Cetirizine Hydrochloride

Press Release Nicox Announces NCX 470 NDA in China Accepted for Review Acceptance of the NCX 470 dossier initiates the review processRegulatory decision expected within 12-18 months from the August submissionQ&A on Ocumension available on Nicox’s website September 11, 2026 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive licensee in China, Ocumension Therapeutics, has received confirmation from China’s National Medical Products Administration (NMPA) that the NCX 470 (also referred to as OT-301 by Ocumension) New Drug Application (NDA) in China has been accepted for review. This acceptance initiates the review of the NDA by the NMPA. Nicox had previously announced the submission of the NCX 470 NDA in China as a treatment to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. “The acceptance for review of the NCX 470 NDA in China initiates the examination process and is another key step towards its commercialisation in this territory. We look forward to continuing to work with the Ocumension team as they prepare for a future launch.” said Gavin Spencer, Chief Executive Officer of Nicox. Ocumension’s Press release is here.Ocumension has paid Nicox license fees of €18 million for the rights to develop and commercialise NCX 470 in the Chinese, Korean and Southeast Asian markets, contributed 50% of the Denali clinical trial costs and is one of Nicox’s principal shareholders. Nicox will receive tiered royalties on sales of NCX 470 made by Ocumension ranging from 6% to 12%. Ocumension already has an ophthalmology sales force in place throughout China and is therefore well-positioned for a rapid launch of NCX 470.There is no fixed period for approval of a pharmaceutical product in China, however the review process typically takes 12 to 18 months following submission. The decision on NCX 470 in China is expected after the decision by the U.S. FDA, who have assigned the PDUFA date1 for 30 April 2027. Key Upcoming NCX 470 Milestones Japan Phase 3 clinical trials results: trials ongoing NDA approval in the U.S.: PDUFA date 30 April 2027U.S. Launch: expected in H2 2027, subject to NDA approvalNDA decision in China: Submission made in August 2026, accepted for review on 10 September 2026 About NCX 470NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. NCX 470 is designed to release bimatoprost and NO into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension. NO is a well-known small, naturally occurring signalling molecule that plays a key role in the regulation of IOP through activation of soluble guanylate cyclase (sGC). NO brings additional IOP-lowering efficacy by enhancing aqueous humor drainage from the eye via a different mechanism of action to that of PGAs.NCX 470 has completed two Phase 3 clinical trials designed to fulfil the regulatory requirements for safety and efficacy to support NDA submissions in the U.S. and China, Mont Blanc and Denali. Both trials were positive and met the efficacy endpoints necessary for submission of a New Drug Application in the United States and China. NDAs for NCX 470 have been submitted in the U.S. and China. NCX 470 is an investigational product and has not yet been approved by the FDA. About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX). For more information www.nicox.com Analyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2025” which are available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 1 A PDUFA date is the target date by which the U.S. Food and Drug Administration (FDA) aims to complete its review and issue a decision on a New Drug Application (NDA) under the Prescription Drug User Fee Act (PDUFA). Attachment EN_NCX470ChinaNDAAcceptanceSeptempber2026_PR_FINAL

NEW YORK, Sept. 5, 2026 /PRNewswire/ -- Consumer365 has reviewed Happy Head for its personalized approach to prescription hair-growth treatment, highlighting a selection of dermatologist-guided formulas designed for men managing thinning hair and male pattern hair loss. Best Hair Growth Products for Men Happy Head - a telehealth provider of personalized, dermatologist-prescribed hair-loss treatments Hair loss treatment has become increasingly personalized as prescription medicine moves into telehealth. Instead of relying on a single standardized formula, Happy Head connects customers with board-certified dermatologists who review medical history, allergies, hair-loss patterns and treatment goals before prescribing a personalized regimen. Treatments are then compounded and shipped directly to the customer. The approach is particularly relevant for consumers researching the best hair growth products for men, a category that includes topical treatments, oral medications and combination regimens. Happy Head offers each format through a telehealth model that does not require an in-person doctor visit. Happy Head offers personalized compounded formulas including dutasteride, finasteride, minoxidil to help you achieve your personal hair growth goals. Consumer365 Recognizes Happy Head's Personalized Treatment Model Consumer365 has recognized Happy Head for combining prescription hair-growth medicine with dermatologist oversight and personalized formulations. Happy Head states that all consultations are conducted by board-certified doctors. The platform also provides ongoing dermatologist support, allowing treatment formulas to be adjusted when medically appropriate. The company's formulations use FDA-approved active pharmaceutical ingredients, although compounded prescription formulations themselves are not FDA-approved. Happy Head's website identifies ingredients such as finasteride and minoxidil among its prescription options. The distinction is important for consumers evaluating prescription hair-loss care. The active ingredients may have established clinical uses, while compounded combinations require individualized medical oversight and are not equivalent to an FDA-approved finished drug product. Happy Head says most customers begin seeing progress within three to six months of consistent daily use. Early changes may include reduced shedding or the appearance of fine new hairs. Individual responses and timelines can vary. TopicalRx SuperSolutionTM ProBlend Topical Rx SuperSolution TM ProBlend is designed for consumers seeking a multi-ingredient topical prescription formula. The formulation includes up to 8% minoxidil alongside ingredients such as dutasteride, finasteride, cetirizine HCl, latanoprost, melatonin, caffeine, tretinoin, vitamin D3 and biotin. The formula is intended to address multiple aspects of hair and scalp health through a single topical treatment. Minoxidil is used to support hair growth, while dutasteride and finasteride target DHT, a hormone associated with male pattern hair loss. Tretinoin is included in the formulation to support minoxidil absorption. Happy Head describes its topical formulations as freshly compounded prescriptions rather than mass-produced products. Formula adjustments are available based on a customer's medical needs and dermatologist assessment. A higher concentration of an active ingredient does not automatically make a treatment appropriate for every person. Prescription-strength formulations require evaluation by a qualified healthcare provider. TopicalRx Solution + SuperCapsuleTM: Dutasteride & MinoxidilRx For men interested in combining topical and oral treatment, Happy Head offers Topical Rx Solution + SuperCapsule TM. The topical solution can contain 0.3% dutasteride, up to 8% minoxidil, retinoic acid and hydrocortisone. The accompanying SuperCapsule contains 0.5 mg dutasteride, 1.25 mg minoxidil and 2,000 IU of vitamin D3. The two-part regimen uses different delivery methods. The topical formula is applied directly to the scalp, for a total of 2.0ml daily, while the capsule provides oral medication once daily. Dutasteride and minoxidil are prescription medications that can carry risks and potential side effects, making medical screening an important part of the process. Happy Head's telehealth assessment is designed to determine whether a prescription treatment is appropriate. Medical history, allergies and the degree of hair loss are among the factors considered during the consultation. SuperCapsuleTM + ED Performance SuperCapsule TM + ED Performance takes a different approach by combining hair-loss treatment with medication for erectile dysfunction in a once-daily capsule. The formulation contains dutasteride, tadalafil and vitamin D3. Dutasteride is used in hair-loss treatment, while tadalafil is a prescription medication used for erectile dysfunction. Happy Head developed the combination for men seeking an oral hair-growth option alongside treatment for sexual performance concerns. The combination also underscores the importance of medical screening. Tadalafil can interact with certain medications and may not be appropriate for people with particular cardiovascular conditions. A dermatologist or other qualified healthcare professional can assess whether the treatment is suitable. The product provides an alternative to a topical routine for men who prefer oral medication. As with other prescription hair-growth treatments, outcomes can vary and consistent use is necessary for evaluating progress. What Sets the Happy Head Model Apart Happy Head's approach centers on prescription treatment supported by telehealth rather than a one-size-fits-all regimen. Customers complete an online assessment before connecting with a board-certified dermatologist. Once a prescription is approved, the treatment is prepared and shipped directly to the customer. Happy Head reports that more than 1 million prescriptions have been delivered through its platform. The company also says its treatments are shipped monthly in discreet packaging, with refills automatically sent as part of eligible subscriptions. Pricing varies according to the formulation and ingredients. Happy Head currently lists custom compounded prescription formulas ranging from $59 to $119 per month. Promotional savings and subscription terms can change over time. For consumers comparing the best hair growth products for men, the key consideration is not simply the number of ingredients or strength of a formula. Hair loss can have different causes, and prescription medications have different safety considerations. A dermatologist-guided assessment can help determine whether topical medication, oral treatment or a combination approach is appropriate. Consumer365's recognition of Happy Head highlights the growing role of personalized telehealth in hair-loss care. With multiple prescription formats and dermatologist oversight, the platform gives men a range of treatment pathways while keeping medical evaluation central to the process. The full review is available at the Consumer365 website. Happy Head offers personalized compounded prescription treatments. Compounded medications are not FDA-approved, and some ingredients or uses discussed may be prescribed off-label. Treatment suitability and results vary. A licensed healthcare provider must determine whether a treatment is appropriate. Review Happy Head's Drug Safety & Information. About Happy Head Happy Head is the industry-leading, dermatologist-founded telehealth company redefining the future of precision hair care. Founded in 2021 by renowned dermatologists and hair loss experts, Dr. Ben Behnam and Dr. Sean Behnam, the company combines clinical expertise with breakthrough science to deliver personalized solutions for hair preservation and restoration. From custom-compound topicals to its innovative StrandIQ™ DNA Starter Kit, Happy Head empowers individuals to make informed decisions to take control of their hair health journey from the privacy of their home, with recommendations that are clinically proven and tailored to individual needs. The mission is simple: help people regrow their hair and restore their confidence with personalized, medical-grade treatments that actually work. Learn more at . About Consumer365.org: Consumer365 provides consumer news and industry insights. As an affiliate, Consumer365 may earn commissions from sales generated using links provided. SOURCE Consumer365.org 21% more press release views with Request a Demo